ACADIA PHARMACEUTICALS INC ACAD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
3.79
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.1B | $391.0M | — | $105.1M | $1.2B |
| 2024 | $957.8M | $226.5M | — | $157.2M | $732.8M |
| 2023 | $726.4M | -$61.3M | $684.8M | $16.7M | $431.8M |
| 2022 | $517.2M | -$216.0M | $507.1M | -$114.0M | $400.4M |
| 2021 | $484.1M | -$167.9M | $473.3M | -$126.8M | $540.9M |
| 2020 | $441.8M | -$281.6M | $431.5M | -$143.8M | $627.0M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.79 (safe)
- Working capital / assets 0.502
- Retained earnings / assets -1.159
- EBIT / assets 0.067
- Equity / liabilities 3.644
Source: SEC EDGAR filings · CIK 0001070494 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.